The Niche - Knoepfler lab stem cell blog

20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020

January 2, 2020 Paul Knoepfler 1

Every year in December and early January I do a post predicting some key events for the stem cell and regenerative medicine field for the upcoming year and today’s post contains my predictions for 2020. You can see my past […]

Jiankui He who claims CRISPR baby production

Perspectives on CRISPR baby guy He Jiankui (贺建奎) going to jail

December 31, 2019 Paul Knoepfler 2

Scientist He Jiankui(贺建奎) has been sentenced to 3 years in prison by Chinese authorities. Two collaborators also will go to jail. A piece in Science by Dennis Normile on the sentencing of He Jiankui ID’d the other two: “His collaborators were identified […]

B+ on my report card on my 20 stem cell predictions for 2019

December 26, 2019 Paul Knoepfler 7

Last year around this time I took my annual plunge to make 20 predictions for the coming year for the stem cell and regenerative medicine field. I even made a crystal ball graphic to highlight the complexity of the stem […]

Masayo Takahashi (高橋政代): exciting vision work advancing including with photoreceptors

December 22, 2019 Paul Knoepfler 1

Masayo Takahashi is a leading stem cell researcher doing translational and clinical research on vision. She’s doing pioneering work on using pluripotent stem cells as a basis for helping patients with vision loss such as due to macular degeneration. She […]

Fig. 4a Schaub, et al JCI 2019. IPS cell work.

1st autologous IPS cell clinical trial for vision loss in the US

December 18, 2019 Paul Knoepfler 11

The NIH announced the launch of the 1st autologous induced pluripotent stem (IPS) cell trial for vision loss in the U.S., focused on macular degeneration. The protocol is based on a solid foundation of pre-clinical animal studies: “Researchers at the […]

The mission of the Knoepfler Lab Blog here at UC Davis School of Medicine is to build stem cell bridges to new treatments and cures through education, outreach, and science.

I encourage readers of this blog to make comments.

There are some rules and key considerations for ipscell.com governing the comments to keep in mind.

Comments will be moderated by a really busy human being so they may not appear right away, particularly if they are very long and/or contain allegations against people or companies, or express inflammatory opinions in which case they may take up to a day or even longer to appear or may never appear.
Comments cannot include personal attacks.
Commenters should avoid being libelous to a person or corporation.
Commenters must use a valid email address.
Commenters generally cannot promote a specific unproven stem cell clinic or physician even by implication.
Commenters are solely responsible for the content of their comments.
I generally do not post comments written by parties referring to other parties who are both involved in an ongoing or pending legal dispute with each other such as litigation. Exceptions to this may be allowed for comments on a blog post that has a topic focused specifically on said legal disputes.
Commenters cannot give medical advice.
Consumers posting comments regarding their opinions of medical treatment they received are solely responsible for that content and readers should understand that such comments reflect opinions, not facts.
Commenters who violate this policy with their submitted comments may temporarily or permanently lose the right to make comments.

By submitting your comment for potential posting on this blog you agree that the comment may be either edited or not posted at all at the blog's discretion if there is concern about non-compliance with this comment policy.

Disclosures

The views expressed on this blog in posts are my own and do not reflect the views of my employer, UC Davis.

I have no financial interests in any stem cell companies or patents in that area.

No material on this website should be considered medical advice and all medical decisions should be discussed with your personal physician first.